Evolutionarily conserved enzyme inhibitors for agriculture and human health applications
Specially designed inhibitor compounds targeting an enzyme that regulates drought tolerance, with differential potency against plant, fungal, and mammalian enzyme homologues. These compounds enable species-specific applications spanning crop yield protection, fungicides, and potential therapeutic development.
Overview
This research presents a portfolio of small-molecule inhibitor compounds designed against an enzyme that regulates drought tolerance in plants. The enzyme is evolutionarily conserved across species, and the inhibitor series exhibits differential potency against plant, fungal, and mammalian enzyme homologues. This selectivity profile creates opportunities for species-specific applications ranging from crop yield protection and antifungal treatments to potential therapeutic leads for human health.
The core value proposition is the repurposing potential of a single chemical scaffold across agriculture and medicine. By developing analogs with tailored selectivity profiles, the research team aims to address multiple market segments with a unified chemical platform, reducing development costs and accelerating timelines compared to de novo discovery for each application.
Technical specifications
- Target class: Small-molecule inhibitors of an evolutionarily conserved enzyme linked to drought tolerance regulation
- Discovery approach: Designed from initial library screen hits, with analoguing guided by differential potency profiling across species homologues
- Selectivity profile: Differentially potent against plant, fungal, and mammalian enzyme variants, enabling species-specific targeting
- Application domains:
- Agriculture: crop yield protection through drought tolerance modulation
- Plant productivity: enhanced resilience and productivity traits
- Antifungal: fungicide development leveraging fungal enzyme inhibition
- Human health: potential therapeutic leads exploiting mammalian homologue activity
- Development stage: Analoguing underway to refine selectivity and expand functional diversity
Technology readiness level
The compounds are at an early research stage. Initial library screening has identified hit compounds, and structure-informed analoguing is now in progress to optimize potency and selectivity across the three target species. Further validation studies are planned to characterize the biological effects of optimized analogs in plant, fungal, and mammalian systems, and to assess their suitability for downstream applications in crop protection, antifungal development, and therapeutic discovery.
About Australian National University
Australian National University is a comprehensive public research university in Canberra with a national mandate and global outlook. Industry partners access on-campus national supercomputing, micro- and nanofabrication capabilities, prototyping spaces, and clinical research pathways through affiliations with the Canberra Hospital. Proximity to Australia’s federal agencies and adjacency to CSIRO enable collaboration on policy, standards, and translational science, while a regional innovation network connects companies to talent and startups. Research is underpinned by competitive national funding, including the Australian Research Council and National Health and Medical Research Council, alongside government and industry contracts. A dedicated technology transfer office and a university-owned enterprise arm support IP, licensing, and spinout creation.
delivered to your inbox.